|
| Press Releases |
|
 |
|
| Monday, April 27, 2015 |
|
|
Eisai and Nihon Medi-Physics Enter Collaboration Agreement to Contribute to Diagnosis and Treatment of Dementia with Lewy Bodies |
| Eisai Co., Ltd. and Nihon Medi-Physics Co., Ltd. announced today that they have entered into a collaboration agreement to contribute to the diagnosis and treatment of dementia with Lewy bodies (DLB) in Japan. more info >> |
|
| Monday, April 13, 2015 |
|
|
Eisai and Genomics Plc to Collaborate in Analyses of Large-Scale Genotype/Phenotype Data to Inform Drug Development |
| Eisai Co., Ltd. and Genomics plc announced today that they have entered into a collaborative agreement to use Genomics' sophisticated statistical analyses of large-scale multi-phenotype genetic association data to inform Eisai's drug discovery process, including target selection, target validation, indication selection and repositioning. more info >> |
|
| Friday, April 3, 2015 |
|
|
Niigata University and Eisai Present Results of Joint Research in U.S. Academic Journal |
| A research group led by Professor Takeshi Ikeuchi of the Department of Molecular Genetics within the Brain Research Institute at Niigata University and Eisai Co., Ltd. announced today that the amount of plasma desmosterol was found to be highly correlated with longitudinal cognitive decline in patients with Alzheimer's disease. more info >> |
|
| Thursday, March 5, 2015 |
|
|
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer |
Eisai Co., Ltd. and Merck announced today a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck's anti-D-1 therapy, pembrolizumab in combination with Eisai oncology compounds lenvatinib mesylate and eribulin mesylate in multiple clinical trials.
more info >> |
|
| Tuesday, March 3, 2015 |
|
|
China JSFDA Accepts Eisai's Application Seeking Additional Indication of Severe Alzheimer's Disease for Aricept |
| Eisai Co., Ltd. announced today that its New Drug Application for the additional indication of severe Alzheimer's Disease (AD) for Aricept(R) has been accepted for review by the Jiangsu Food and Drug Administration in China. more info >> |
|
| Monday, March 2, 2015 |
|
|
Eisai Launches Anticancer Agent Lenvima in the United States |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) as a treatment for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer in the United States on February 26, 2015. more info >> |
|
| Wednesday, February 25, 2015 |
|
|
Eisai to Establish Oral Solid Dose Production Facility at New Suzhou Plant in China |
| Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has decided to build a new oral solid dose (OSD) production facility at the site of its new Suzhou plant ("New Plant") located within the Suzhou Industrial Park in order to relocate and expand its existing OSD production facility ("Old Plant") within the same industrial park. more info >> |
|
|
Eisai Announces Phase III Trial of Anticancer Agent Halaven in Soft Tissue Sarcoma Shows Overall Survival Benefit in Primary Endpoint |
| Eisai Co., Ltd. announced today that in a Phase III clinical trial (Study 309) of its in-house discovered and developed anticancer agent eribulin mesylate in patients with soft tissue sarcomas, eribulin demonstrated a statistically significant extension in overall survival (OS) over the comparator treatment dacarbazine, and the study met its primary endpoint. more info >> |
|
| Tuesday, February 24, 2015 |
|
|
Additional Exploratory Analysis of Phase II Trial Suggests Anticancer Agent Lenvatinib Extends Overall Survival in Patients with Advanced Non-small Cell Lung Cancer |
| Eisai Co., Ltd. announced today the latest results of an additional exploratory analysis of a Phase II clinical trial (Study 703) of its in-house developed anticancer agent lenvatinib mesylate (Lenvima(TM)) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed at least two systemic anticancer regimens. more info >> |
|
| Thursday, February 19, 2015 |
|
|
Eisai Receives Approval in Japan for Fine Granule Formulation of Anti-Arrhythmic Agent Tambocor Suitable for Pediatric Patients |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received marketing and manufacturing approval in Japan for Tambocor Fine Granules 10%, a new formulation of anti-arrhythmic agent Tambocor (flecainide acetate). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
ZeroPath Corp. Launches Next-Generation Code Security Platform Powered by Artificial Intelligence
Jan 23, 2025 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES Develops AgSn TLP Sheet, a Sheet-type Bonding Material for Power Semiconductors 
Jan 23, 2025 11:00 JST
|
|
|
Tamkeen Launches 'Bahrain Skills and Gender Parity Accelerator' at Davos
Jan 23, 2025 08:00 HKT/SGT
|
|
|
The Now Corporation (OTC:NWPN) Subsidiary, Green Rain Solar Inc., Explores Selling Development Rights for Solar Farm Project in Greece, NY
Jan 22, 2025 21:00 HKT/SGT
|
|
|
MHI Receives Order for 3 New Series Trainsets (12 Cars) for Seibu Railway's Yamaguchi Line
Jan 22, 2025 17:27 JST
|
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
Jan 22, 2025 17:18 JST
|
|
|
2nd Annual Operational Excellence & Business Transformation Summit: Operational Excellence in The Age of Digital Transformation, Building A Sustainable and Collaborative Future in Asia
Jan 22, 2025 16:15 HKT/SGT
|
|
|
Introducing the Sonim XP400: a 5g Smartphone Engineered for Demanding Days with Unmatched Durability, Now Available in EMEA and Australia
Jan 22, 2025 15:09 HKT/SGT
|
|
|
ACN Newswire and Corinium Intelligence Present: CISO Perth 2025 - Uniting Western Australia's Top InfoSec Leaders
Jan 22, 2025 14:28 HKT/SGT
|
|
|
ASEAN Finance Innovation Summit 2025: Unlocking the Future of Finance
Jan 22, 2025 14:25 HKT/SGT
|
|
|
Second Hong Kong Shopping Festival gets underway with seminars and consultancy services
Jan 22, 2025 11:54 HKT/SGT
|
|
|
Migrant Workers Honored at Indian New Year Celebrations
Jan 22, 2025 11:40 HKT/SGT
|
|
|
The Now Corporation (OTC: NWPN) Sees Opportunities for Community Solar Projects in California
Jan 21, 2025 21:00 HKT/SGT
|
|
|
Celebrate Chinese New Year with Vibrant Festivities at Spritzer EcoPark
Jan 21, 2025 18:29 HKT/SGT
|
|
|
Mitsubishi Power Advances Thailand's Energy Development with Completion of 1,400MW Combined Cycle Hin Kong Power Plant
Jan 21, 2025 16:24 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
